Emerald Advisers’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-620,370
Closed -$7.43M 250
2022
Q3
$7.43M Sell
620,370
-1,242,252
-67% -$15.4M 0.38% 91
2022
Q2
$15.6M Sell
1,862,622
-86,955
-4% -$674K 0.8% 49
2022
Q1
$16.9M Buy
1,949,577
+178,658
+10% +$1.72M 0.65% 64
2021
Q4
$20M Buy
1,770,919
+254,916
+17% +$3.03M 0.74% 58
2021
Q3
$19.1M Buy
1,516,003
+239,007
+19% +$2.2M 0.69% 59
2021
Q2
$10.4M Buy
1,276,996
+825,566
+183% +$7.16M 0.38% 98
2021
Q1
$4.18M Buy
+451,430
New +$4.55M 0.15% 120

Other funds holding GOSS

Emerald Advisers's GOSS Position: Q4 2022 in Review

Emerald Advisers sold out of Gossamer Bio (GOSS) in Q4 2022, closing a stake of 620,370 shares — an estimated $7.43M sold.

Emerald Advisers first reported a position in GOSS in Q1 2021 and held it in 7 quarters. The position peaked at $20M in Q4 2021. 120 funds tracked by Wall St. Rank hold GOSS as of Q4 2022.

  • Emerald Advisers reported no remaining Gossamer Bio position as of Q4 2022 after selling out during the quarter.
  • Emerald Advisers sold 620,370 Gossamer Bio shares in Q4 2022, an estimated $7.43M.
  • Emerald Advisers first reported a position in Gossamer Bio in Q1 2021 and held it in 7 quarters.
  • Emerald Advisers's Gossamer Bio position peaked at $20M in Q4 2021.
  • 120 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2022.

Based on Emerald Advisers's 13F filing for Q4 2022, filed 3 Feb 2023.